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Abstract
After almost a year of COVID-19, the chronic long-COVID syndrome has been recognized as an entity in 2021. The patients with the long-COVID are presenting with
ominous neurological deficits that with time are becoming persistent and are causing
disabilities in the affected individuals. The mechanisms underlying the neurological
syndrome in long-COVID have remained obscure and need to be actively researched
to find a resolution for the patients with long-COVID. Here, the factors like site of
viral load, the differential immune response, neurodegenerative changes, and inflammation as possible causative factors are debated to understand and investigate the
pathogenesis of neuro-COVID in long-COVID syndrome.
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Long-COVID syndrome is a complex chronic clinical manifestation of signs and symptoms in patients who have experienced

Infections caused by SARS-CoV-2 have not only resulted in a gigantic

the SARS-C oV-2 infection without complete recovery from the

number of morbidities and mortalities worldwide in COVID-
19, but

COVID-19.

its ability to cause a protracted illness in form of long-COVID is now

A growing fraction of the COVID-19 patients are emerging with

becoming increasingly evident.2 The syndromic manifestation in long-

continuing effects of the disease, with complaints like mental fog,

COVID has shown to become chronic and the affected individuals are

delayed latent periods in recalling events of the recent past, tachy-

seen to be predominately exhibiting neurological deficits which are

cardia, and extreme fatigue.1 In the case where Long-COVID syn-

worrying. The most daunting task in long-COVID is to understand the

drome is not observed after SARS-CoV-2 infections, patients have

mechanisms underlying mechanism in general and the pathogenesis of

been reported to turn asymptomatic before or within 8–12 weeks

neurological signs and symptoms in particular. Debated here are local

after COVID-19. There have been attempts to draw a timeline for

routes and systemic mechanisms by which SARS-CoV-2 can involve

Long-COVID and clinical findings persisting beyond 3 weeks after

the nervous system to evoke a low-grade smoldering neuronal injury

the acute short phase was recommended to be considered for Long-

that possibly contributes to the neurological deficits reported. A bet-

2

COVID syndrome though cases are appearing even 3 months after

ter understanding of the route and pathways of the SARS-CoV-2 in the

the acute phase of COVID-19.

causation of the neurological deficits is expected to develop targeted
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therapies in long-COVID syndrome to minimize the disabilities resulting

not the only reason behind protracted neurological signs and symp-

in the affected patients. Additionally, a history of pre-COVID existing

toms seen in long-COVID. The inflammation (Figure 1, C2) around

neurological deficit should be taken into account to identify newer neu-

the OM, cribriform plate, and OB to the presence of SARS-CoV-26

rological sign and symptoms caused by COVID. A differential diagnosis

could become the basis of continuation of anosmia and hypogeusia

with post-traumatic stress disorder (PTSD) caused by the pandemic ap-

in long-COVID. Similar mechanisms involving the regions around the

pears to be important.

frontal lobe (Figure 1, A) (in proximity to the olfactory bulbs) with

Also feature like facial drooping, and speech-
related deficits

a sub-clinical low-grade inflammation can be the possible basis of

which are potential signs of stroke can be blunted by a patient's face

“brain fog,” cognitive functional deficits, persistent headaches, and

mask, wearing of which is common during the COVID-19 pandemic.3

diverse neurological findings (Figure 1C) seen in long-COVID.

3 | S ITE S O F V I R A L LOA D A N D TH E I R
S I G N I FI C A N C E I N N EU RO - C OV I D

6 | D I FFE R E NTI A L S Y N D RO M I C
M A N I FE S TATI O N I N N EU RO - C OV I D

Central to the understanding of the neurological deficits caused by

The neurological deficits exhibited in COVID-19 are known to differ

SARS-CoV-2 is the ability of this virus to seed specific sites in human

widely among the patients infected with SARS-CoV-2. One exam-

tissues, which can enable its access to the central nervous system

ple is loss of smell (anosmia) and altered sense of taste (hypogeusia),

(CNS). Nasal and oral cavity are known sites of SARS-CoV-2 seed-

presence or absence of seizures, loss of consciousness, and difficul-

ing from which samples are collected to diagnose COVID-19. The

ties with involuntary breathing mechanics, which vary in their inten-

nasal cavity, in particular, is anatomically extended to regions bear-

sity from patient to patient. Also, the fact that a significant number

ing neurological tissues like olfactory mucosa (OM), and across the

of patients never enter the long-COVID phase needs to be investi-

cribriform plate, at the root of the nose (Figure 1A), to the olfactory

gated and understood in-depth. The extent of the viral load and CNS

bulb (OB) and frontal lobe of the brain (Figure 1A-A1). Though the

entry along with differential immune response among the affected

oral cavity has no direct extensions to the CNS, the infection of the

patients may explain these disparities observed and could be the

nerve terminals in the mouth via retrograde neuronal transport can

basis of the protracted course of COVID-19 in that becomes chronic

enable the SARS-CoV-2 to reach cardinal regions of the CNS like the

to manifest as long-COVID.7 Mechanisms in particular where an in-

2

brainstem (Figure 1A). Common to both of the above routes is its

complete clearance of the SARS-CoV-2 is involved can linger on for

extension to the lungs (Figure 1B), which is a known organ to be

months and its clearance might help as supported by the findings

involved in SARS-CoV-2 infection in acute as well as long-COVID.

in 30 to 40% of those who get the vaccine have reported improvements to their symptoms. The fact that vaccination provokes the

4 | PRO G R E S S I V E N EU ROTRO PI C
D EG E N E R ATI V E E FFEC T S O F SA R S - C oV-2

formation of antibodies and T-killer cells, which may clear the residual SARS-CoV-2 from the body, appears to be one possible reason
and an explanation for the improvements mentioned above in the
neurological signs and symptoms of long-COVID.

One of the possible reasons for the observation of neurological deficits in long-COVID 4 (Figure 1C), is a possibly a slowly progressive degenerative effect of the SARS-CoV-2 following the neuronal entry.
Such finding has been reported recently to affected patients and it

7 | PE R S I S TE N C E O F V I R A L LOA DS AT
I M M U N O LO G I C A LLY PR I V I LEG E D S ITE S

should be no surprise to see the degenerative processes5 (Figure 1,
C1), reflecting as neurological deficits. Though the underlying mech-

Among diverse reasons for incomplete clearance of SARS-CoV-2

anisms leading to neuronal damage are yet to be completely under-

from the human body by the immune system after 2–3 weeks of the

stood, neuronal atrophy, hypometabolism, and defects induced in

COVID-19 infection is the possible ability of the virus to reside at im-

synaptic transmission can be the covert pathways induced by SARS-

munologically privileged sites, from where its arrival into the circula-

CoV-2 in long-COVID to inflict neuronal damage.

tion can lead to a protracted course of illness leading to long-COVID.
The eyes, lacrimal sac,8 testes, and placenta are few examples where
SARS-CoV-2 can conceal itself, but why this is not the case with pa-

5 | P OS S I B LE RO LE O F TH E
I N FL A M M ATO RY R E S P O N S E TO SA R S -
C oV-2 I N FEC TI O N I N C AU SATI O N O F TH E
C N S M A N I FE S TATI O N I N LO N G - C OV I D
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The immunologically mediated cytokine release by glia and lympho-

The magnitude with which the human immune system would re-

cytes at the site of viral load and infection may offer an additional if

spond to COVID-19 differs from person to person for few apparent

tient's not exhibiting long-COVID remains to be resolved.
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F I G U R E 1 Long-COVID: CNS Access and NeuroCOVID syndrome. SARS-CoV-2 viral loads can follow anatomical pathways from the nasal
cavity to the brain (A-A1) via the cribriform plate of the ethmoid bone (A1) and the lungs via respiratory passages (B). Patients in long-COVID
report diverse neurological signs and symptoms (C-list) that can be due to slow neuronal damage (C1) (neurodegeneration) or due to low-
grade inflammation and cytokine-mediated damage (C2). SARS-CoV-2 has been isolated from beneath the cribriform plate and the neurons
of the frontal lobe in COVID-19 patients
reasons, that includes, (a) the viral load, (b) the ACE2 expression lev9

in long-COVID. The neurological deficits in long-COVID 4 were pre-

els in the tissues, and (c) the diversity of immune response. It ap-

dicted to impose a huge burden on the healthcare profession and it

pears that following an acute phase if the removal of SARS-CoV-2

now is proving itself a major cause of disability in the post-acute-

is not substantial enough, the sub-acute infection persists and be-

COVID patient group.

comes chronic to exhibit as long-COVID. Of the sites that suffer the
effects of the residual virus and the inflammation that accompanies
it, the CNS is the most venerable tissue. The latter is because of the
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inability of the neurons to regenerate following damage caused by
either the virus (Figure 1, C1) or cytokines generated by the low-

Research that includes long-COVID patients with neurological defi-

grade inflammation (Figure 1, C2). Other tissues that can regener-

cits for understanding the basic underlying pathogenesis of neuro-

ate following the cellular injury, do not dominate the symptomatic

COVID is needed and the NeuroCOVID project is one example.4 The

picture of long-COVID as a partial restoration of function is likely

biological fluids of these patients need to be fully analyzed for cy-

following COVID-19. The finding that vaccinations help some pa-

tokines. Imaging the CNS to notice morphological changes induced

tients with long-COVID,7 needs in-depth research to find the sup-

in long-COVID is also required as the images can be compared in the

port the vaccination offers to a chronic symptomatic long-COVID

coming years to see if the findings progress or remain static. Clinical

patient at the pathogenetic level. Stimulation of a weakly provoked

assessment and appropriate treatment regimens are also essentially

immune system to eradicate the virus seems to be one possibility,

needed as if not halted in time, the neurological deficits may become

but other mechanisms may be at play that is yet to be elucidated

a permanent disability that would not revert.
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